explore -WSS

explore

author：fashion 2025-09-14 22:00:51 - browse：1

This is the inaugural edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

Hello! Welcome to the premiere issue of Adam’s Biotech Scorecard. I’m excited to get started. Let’s do this! (By the way, the AF in the logo are my initials, not the “other” AF.)

The contrarian view of Viking Therapeutics

Closeup financial chart

The developer of a dual-acting GLP-1/GIP treatment for obesity is riding high on positive data and takeout speculation. The drug, called VK2735, has shown impressive weight loss with minimal gastrointestinal side effects in both subcutaneous and oral formulations, positioning it as a strong challenger to the obesity juggernauts from Eli Lilly and Novo Nordisk. With a stock price that has soared nearly 800% over the past year, Viking is now a $9 billion company and a prime acquisition target for a cash-rich pharma company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Syphilis numbers in the United States reach record heights

hotspot

WSS

Wegovy leads to weight loss. Can it treat depression, too?

White House pharmacy plagued with problems, investigation finds

10 reasons why health care startups fail

Vertex non

Health Care Service Corp to buy Cigna Medicare Advantage plans

Flash flood warnings continue for parts of Missouri, Illinois

focus

explore

The contrarian view of Viking Therapeutics

leisure time

What does generative AI mean for health care? We asked experts

Venture capital firm's plans to take over Akron hospital face hurdles

ChatGPT in medicine: STAT answers readers' burning questions

Election results set back Medicaid expansion plans

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Google's generative AI to analyze medical images — and talk to docs

Virginia high school admissions case could be legal follow

Tuberculosis patients need more than just free medication

Walensky prepares to leave CDC — and Congress — behind

Failure, not just success, should guide future doctors

knowledge

Health Care Service Corp to buy Cigna Medicare Advantage plans

Flash flood warnings continue for parts of Missouri, Illinois

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Paxlovid rebound happens. Why and to whom are still a mystery

With heat waves through August, officials warn of health risks

FTC sues over Novant Health acquisition of two N.C. hospitals

hotspot

focus

hotspot

hotspot